Literature DB >> 26712049

Fibrolamellar carcinoma versus scirrhous hepatocellular carcinoma : diagnostic usefulness of CD68.

Faten Limaiem, Saadia Bouraoui, Maroua Sboui, Sirine Bouslama, Ahlem Lahmar, Sabeh Mzabi.   

Abstract

BACKGROUND: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare variant of hepatocellular carcinoma that commonly affects young individuals without a prior history of liver disease. The principal differential diagnosis is conventional hepatocellular carcinoma especially the scirrhous variant. Despite their distinctive appearance, recent studies have demonstrated a lack of consistency in how FL-HCC are diagnosed by pathologists. AIM: To investigate the diagnostic utility of CD68 in differentiating between FL-HCC and scirrhous hepatocellular carcinoma. PATIENTS AND METHODS: In our retrospective study, we reviewed four cases of FL-HCC that were diagnosed at the pathology department of Mongi Slim hospital over a thirteen-year period (2002-2014). Relevant clinical information and microscopic slides were available in all cases and were retrospectively reviewed. Immunohistochemical analysis was performed using the avidin-biotin complex technique with antibodies against CD68 and CK7.
RESULTS: Our study group included one man and three women (sex ratio M/F=0.33) aged between 23 and 34 years (mean=28 years). All cases arose in non-cirrhotic liver. Immunohistochemically, all cases were positive for CK7 and for CD68 (n=4).
CONCLUSIONS: CD68 immunostaining is a sensitive marker for FL-HCC that may be of use in routine diagnostic surgical pathology. Lack of CD68 staining should suggest caution in making a diagnosis of FL-HCC. © Acta Gastro-Enterologica Belgica.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26712049

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  3 in total

1.  Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features.

Authors:  Anastasia Murtha-Lemekhova; Juri Fuchs; Erik Schulz; Anthe Suzan Sterkenburg; Philipp Mayer; Jan Pfeiffenberger; Katrin Hoffmann
Journal:  J Hepatocell Carcinoma       Date:  2021-10-22

2.  Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma.

Authors:  Xiaoyuan Chen; Yiwei Lu; Xiaoli Shi; Guoyong Han; Long Zhang; Chuangye Ni; Jie Zhao; Yun Gao; Xuehao Wang
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

3.  Human liver organoids for disease modeling of fibrolamellar carcinoma.

Authors:  Nicole J C Narayan; David Requena; Gadi Lalazar; Lavoisier Ramos-Espiritu; Denise Ng; Solomon Levin; Bassem Shebl; Ruisi Wang; William J Hammond; James A Saltsman; Helmuth Gehart; Michael S Torbenson; Hans Clevers; Michael P LaQuaglia; Sanford M Simon
Journal:  Stem Cell Reports       Date:  2022-07-07       Impact factor: 7.294

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.